Back to top
more

Precigen (PGEN)

(Delayed Data from NSDQ)

$1.41 USD

1.41
413,594

+0.01 (0.71%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.41 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PGEN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Precigen, Inc. [PGEN]

Reports for Purchase

Showing records 1 - 20 ( 22 total )

Company: Precigen, Inc.

Industry: Medical Services

Record: 1

03/20/2024

Company Report

Pages: 7

PRGN-2012 Launch on the Horizon; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Precigen, Inc.

Industry: Medical Services

Record: 2

11/10/2023

Company Report

Pages: 6

Focus on PRGN-2012; Pipeline Progress Continues; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Precigen, Inc.

Industry: Medical Services

Record: 3

08/10/2023

Company Report

Pages: 7

FDA Agrees a Favorable Regulatory Pathway for PRGN-2012; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Precigen, Inc.

Industry: Medical Services

Record: 4

05/11/2023

Company Report

Pages: 8

Eyes on PRGN-2012 Regulatory Pathway and PRGN-2009 ASCO Update; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Precigen, Inc.

Industry: Medical Services

Record: 5

03/07/2023

Company Report

Pages: 8

Balance Sheet Strengthened; PRGN-2009 Updates Throughout 2023; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Precigen, Inc.

Industry: Medical Services

Record: 6

11/10/2022

Company Report

Pages: 7

PRGN-2012 Update on R&D Day; PRGN-3006 Data at ASH; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Precigen, Inc.

Industry: Medical Services

Record: 7

08/09/2022

Company Report

Pages: 7

UltraCAR-T Platform Achieved Manufacturing Milestone; Lower PT to $6; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Precigen, Inc.

Industry: Medical Services

Record: 8

07/06/2022

Daily Note

Pages: 3

Trans Ova Divesture Removes Financial Overhang; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 5.00

Research Provided by a Third Party

Company: Precigen, Inc.

Industry: Medical Services

Record: 9

05/16/2022

Company Report

Pages: 6

Steady Progress in Clinical Programs; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Precigen, Inc.

Industry: Medical Services

Record: 10

03/02/2022

Company Report

Pages: 7

Clinical Pipeline Development on Target; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Precigen, Inc.

Industry: Medical Services

Record: 11

12/14/2021

Company Report

Pages: 7

Positive PRGN-3006 Update at ASH; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Precigen, Inc.

Industry: Medical Services

Record: 12

11/05/2021

Daily Note

Pages: 5

Solid Progress Across Pipeline, our Take from R&D Day; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 5.00

Research Provided by a Third Party

Company: Precigen, Inc.

Industry: Medical Services

Record: 13

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for PGEN

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Precigen, Inc.

Industry: Medical Services

Record: 14

08/10/2021

Company Report

Pages: 8

All Eyes on the Upcoming R&D Day; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Precigen, Inc.

Industry: Medical Services

Record: 15

05/11/2021

Company Report

Pages: 7

Multiple Clinical Readouts Expected in 2H21; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Precigen, Inc.

Industry: Medical Services

Record: 16

03/02/2021

Company Report

Pages: 7

Encouraging Clinical Updates on UltraCAR-T Programs; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Precigen, Inc.

Industry: Medical Services

Record: 17

12/16/2020

Company Report

Pages: 9

UltraCAR-T Platform’s Potential Validated; Higher PT to $10; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Precigen, Inc.

Industry: Medical Services

Record: 18

11/10/2020

Company Report

Pages: 7

Data-Rich December; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Precigen, Inc.

Industry: Medical Services

Record: 19

08/12/2020

Company Report

Pages: 8

UltraCAR-T Initial Readouts Remain on Track; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Precigen, Inc.

Industry: Medical Services

Record: 20

08/10/2020

Daily Note

Pages: 3

Emerging Opportunity Beyond Oncology; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party